Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401059 | 0.84 | SMN1; SMN2 (0.59) | CDC25BPKMSMN1; SMN2KMT2ATP53 | |
| SCHEMBL6293695 | 0.84 | SMN1; SMN2 (0.59) | CDC25BPKMSMN1; SMN2KMT2ATP53 | |
| SCHEMBL2590708 | 0.84 | L3MBTL1 (0.53) | CDC25BPKMSMN1; SMN2KMT2ANEU3 | |
| SCHEMBL27890841 | 0.82 | L3MBTL1 (0.52) | CDC25BPKMSMN1; SMN2KMT2ANEU3 | |
| SCHEMBL31325736 | 0.82 | HTT (0.47) | CDC25BPKMSMN1; SMN2KMT2ANEU3 | |
| SCHEMBL29499772 | 0.82 | LMNA (0.51) | CDC25BPKMSMN1; SMN2KMT2ANEU3 | |
| SCHEMBL8780064 | 0.82 | HTT (0.47) | CDC25BPKMSMN1; SMN2KMT2ANEU3 | |
| SCHEMBL28669838 | 0.82 | TSHR (0.57) | CDC25BSMN1; SMN2KMT2ATSHRTDP1 | |
| SCHEMBL4597784 | 0.82 | LMNA (0.51) | CDC25BPKMSMN1; SMN2KMT2ANEU3 | |
| SCHEMBL6764607 | 0.82 | CDC25B (0.58) | CDC25BPKMSMN1; SMN2KMT2ANEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CDC25B 1341/4885PKM 2818/4885SMN1; SMN2 3613/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CDC25B 1471/4885PKM 2905/4885SMN1; SMN2 3709/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CDC25B 1341/4885PKM 2818/4885SMN1; SMN2 3613/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CDC25B 1341/4885PKM 2818/4885SMN1; SMN2 3613/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CDC25B 1471/4885PKM 2905/4885SMN1; SMN2 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.